We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pelikan Technologies Acquires Inventus BioTech

By Labmedica staff writers
Posted on 28 Dec 2004
A leading developer of handheld diagnostic products, Pelikan Technologies, Inc. More...
(Palo Alto, CA, USA), has acquired Inventus BioTech GmbH & Co. KG (Munster, Germany) and renamed the company Albatros Technologies GmbH & Co. KG. Financial terms were not disclosed.

The acquisition provides Pelikan with the Inventus GlucoSens sensor, an innovative electrochemical device designed to measure blood glucose and also other analytes. This gives Pelikan the necessary technology and intellectual property to finalize development of its next-generation, fully integrated lancing and glucose-monitoring system for the management of diabetes. In addition, the company also gains access to the critical sensor manufacturing facilities and processes of Inventus. Pelikan has retained the entire Inventus employee base that will now contribute to the accelerated development of its glucose-monitoring system.

The new system will combine the Pelikan Sun electronic lancing product with the one-step glucose-measurement technology of Inventus. An integrated 50-test disposable disk eliminates the need to handle messy strips or sharp lancets, enhancing both safety and convenience. Precise control works with 30 depth settings to allow people of all ages and skin types to reliably lance their skin to the shallowest depth possible. As a result, pain is reduced and skin-healing improved.

"These advantages position the technology as a perfect fit for Pelikan and the company's objective of revolutionizing the mangement of diabetes,” said Prof. Anthony Turner, Ph.D., DSc, head of Pelikan's scientific advisory board. Pelikan was spun off from Agilent Technologies in 2001.





Related Links:
Pelikan Technologies

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.